These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 27039149)
1. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149 [TBL] [Abstract][Full Text] [Related]
2. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276 [TBL] [Abstract][Full Text] [Related]
3. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). Smith B; Lyakhov I; Loomis K; Needle D; Baxa U; Yavlovich A; Capala J; Blumenthal R; Puri A J Control Release; 2011 Jul; 153(2):187-94. PubMed ID: 21501640 [TBL] [Abstract][Full Text] [Related]
4. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma. Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343 [TBL] [Abstract][Full Text] [Related]
5. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Amin M; Badiee A; Jaafari MR Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663 [TBL] [Abstract][Full Text] [Related]
6. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. Arabi L; Badiee A; Mosaffa F; Jaafari MR J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722 [TBL] [Abstract][Full Text] [Related]
7. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. Shmeeda H; Tzemach D; Mak L; Gabizon A J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844 [TBL] [Abstract][Full Text] [Related]
8. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Moosavian SA; Abnous K; Badiee A; Jaafari MR Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819 [TBL] [Abstract][Full Text] [Related]
9. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718 [TBL] [Abstract][Full Text] [Related]
10. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. Alavizadeh SH; Akhtari J; Badiee A; Golmohammadzadeh S; Jaafari MR Expert Opin Drug Deliv; 2016; 13(3):325-36. PubMed ID: 26578208 [TBL] [Abstract][Full Text] [Related]
11. Surrogate MRI markers for hyperthermia-induced release of doxorubicin from thermosensitive liposomes in tumors. Peller M; Willerding L; Limmer S; Hossann M; Dietrich O; Ingrisch M; Sroka R; Lindner LH J Control Release; 2016 Sep; 237():138-46. PubMed ID: 27364227 [TBL] [Abstract][Full Text] [Related]
12. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models. Jia D; Yang Y; Yuan F; Fan Q; Wang F; Huang Y; Song H; Hu P; Wang R; Li G; Liu R; Li J Int J Pharm; 2020 Aug; 586():119541. PubMed ID: 32544521 [TBL] [Abstract][Full Text] [Related]
13. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer. Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311 [TBL] [Abstract][Full Text] [Related]
14. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors. Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382 [TBL] [Abstract][Full Text] [Related]
15. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index. Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964 [TBL] [Abstract][Full Text] [Related]
16. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide. Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376 [TBL] [Abstract][Full Text] [Related]
17. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937 [TBL] [Abstract][Full Text] [Related]
18. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation. Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cells. Lee YH; Ma YT J Nanobiotechnology; 2017 May; 15(1):41. PubMed ID: 28521752 [TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors. Kibria G; Hatakeyama H; Sato Y; Harashima H Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]